Programs and Projects
Skin Cancer Clinical Trials - University of Arizona
Contact: H-H. Sherry Chow, PhD
DCP Program Director: Joe Tangrea, MPH, PhD
The purpose of this study is to evaluate the potential of Sulindac, a non-steroidal anti-inflammatory drug, as a chemopreventive agent for skin cancer.
Men and women with ≥ 4 large atypical moles and one benign mole may be eligible to participate in this study. Those taking part in the study will receive Sulindac or placebo by mouth for 8 weeks. Participants will undergo biopsy of skin lesions before and after receiving study treatment. The study is being conducted at the University of Arizona, Arizona Cancer Center and Stanford University. As of February 2009, sites are actively accruing participants to this trial.
[This is a phase 2 randomized double-blind placebo controlled multicenter trial of Sulindac compared to placebo for the prevention of skin cancer. Clinical and dermascopic evaluation will be performed on healthy individuals with ≥ 4 clinical atypical nevi and ≥ 1 benign nevus suitable for biopsy. Participants will receive 8 weeks of study medication. Participants will undergo pre-intervention and post-intervention biopsy of skin lesions.]